CN104114179A - 用于治疗钙吸收不良和骨代谢紊乱的无定形碳酸钙 - Google Patents

用于治疗钙吸收不良和骨代谢紊乱的无定形碳酸钙 Download PDF

Info

Publication number
CN104114179A
CN104114179A CN201280069595.5A CN201280069595A CN104114179A CN 104114179 A CN104114179 A CN 104114179A CN 201280069595 A CN201280069595 A CN 201280069595A CN 104114179 A CN104114179 A CN 104114179A
Authority
CN
China
Prior art keywords
calcium
acc
bone
experimenter
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280069595.5A
Other languages
English (en)
Chinese (zh)
Inventor
阿米尔·萨希
阿萨夫·瑟尔特
盖利特·薛泰尔-高德
麦克·丹尼利
欧尔文·梅伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorphical Ltd
Original Assignee
Amorphical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorphical Ltd filed Critical Amorphical Ltd
Priority to CN201910013584.9A priority Critical patent/CN109568338A/zh
Publication of CN104114179A publication Critical patent/CN104114179A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201280069595.5A 2011-12-13 2012-12-13 用于治疗钙吸收不良和骨代谢紊乱的无定形碳酸钙 Pending CN104114179A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910013584.9A CN109568338A (zh) 2011-12-13 2012-12-13 用于治疗钙吸收不良和骨代谢紊乱的无定形碳酸钙

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161569805P 2011-12-13 2011-12-13
US61/569,805 2011-12-13
US201261680721P 2012-08-08 2012-08-08
US61/680,721 2012-08-08
PCT/IL2012/050521 WO2013088440A1 (en) 2011-12-13 2012-12-13 Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910013584.9A Division CN109568338A (zh) 2011-12-13 2012-12-13 用于治疗钙吸收不良和骨代谢紊乱的无定形碳酸钙

Publications (1)

Publication Number Publication Date
CN104114179A true CN104114179A (zh) 2014-10-22

Family

ID=48611949

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280069595.5A Pending CN104114179A (zh) 2011-12-13 2012-12-13 用于治疗钙吸收不良和骨代谢紊乱的无定形碳酸钙
CN201910013584.9A Pending CN109568338A (zh) 2011-12-13 2012-12-13 用于治疗钙吸收不良和骨代谢紊乱的无定形碳酸钙

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910013584.9A Pending CN109568338A (zh) 2011-12-13 2012-12-13 用于治疗钙吸收不良和骨代谢紊乱的无定形碳酸钙

Country Status (10)

Country Link
US (2) US10064890B2 (cg-RX-API-DMAC7.html)
EP (1) EP2790710B1 (cg-RX-API-DMAC7.html)
JP (3) JP2015500333A (cg-RX-API-DMAC7.html)
CN (2) CN104114179A (cg-RX-API-DMAC7.html)
AU (3) AU2012354056B2 (cg-RX-API-DMAC7.html)
CA (2) CA3056570C (cg-RX-API-DMAC7.html)
DK (1) DK2790710T3 (cg-RX-API-DMAC7.html)
ES (1) ES2831699T3 (cg-RX-API-DMAC7.html)
IL (2) IL233107B (cg-RX-API-DMAC7.html)
WO (1) WO2013088440A1 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107921060A (zh) * 2015-06-04 2018-04-17 艾玛菲克有限公司 用于吸入施用、舌下施用或含服施用的无定形碳酸钙的组合物
CN108778296A (zh) * 2016-01-18 2018-11-09 艾玛菲克有限公司 治疗神经、肌肉和不育疾病或状况的稳定的无定形碳酸钙
CN110121351A (zh) * 2016-10-25 2019-08-13 艾玛菲克有限公司 用于治疗白血病的无定形碳酸钙
CN110123836A (zh) * 2019-05-20 2019-08-16 昆明朗盛生物科技有限公司 钙锌维生素d泛酸片的应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150374747A1 (en) * 2013-02-11 2015-12-31 Amorphical Ltd. Amorphous calcium carbonate for accelerated bone growth
CA2956048C (en) 2014-07-31 2023-01-24 Amorphical Ltd. Encapsulated amorphous calcium carbonate compositions
US12121538B2 (en) 2015-06-04 2024-10-22 Amorphical Ltd. Compositions of amorphous calcium carbonate for inhalation, sublingual or buccal administration
JP2017032550A (ja) * 2015-07-30 2017-02-09 大塚製薬株式会社 胃粘膜萎縮の有無を判定する方法
US12629390B2 (en) 2016-01-18 2026-05-19 Amorphical Ltd. Stabilized amorphous calcium carbonate for treatment of neurological, muscular and infertility diseases or conditions
AU2017210259B2 (en) 2016-01-18 2022-11-03 Amorphical Ltd. Stabilized amorphous calcium carbonate as a supplement for cell culture media
US20230365935A1 (en) * 2016-01-18 2023-11-16 Amorphical Ltd. Stabilized amorphous calcium carbonate as a supplement for cell culture media
JP6872680B2 (ja) * 2016-03-22 2021-05-19 国立大学法人 宮崎大学 カルシウム吸収促進剤
MX2022000947A (es) 2019-07-23 2022-04-26 Amorphical Ltd Carbonato de calcio amorfo para mejorar el rendimiento deportivo.
BR112022018055A2 (pt) * 2020-03-11 2022-10-18 Amorphical Ltd Carbonato de cálcio amorfo para tratamento de acidose.
WO2021226064A1 (en) * 2020-05-04 2021-11-11 University Of Louisville Research Foundation, Inc. Artificial intelligence-based systems and methods for dosing of pharmacologic agents
MX2023002801A (es) * 2020-09-15 2023-04-21 Oncoinvent As Particulas radiomarcadas de tama?o controlado.
JP7573310B2 (ja) * 2022-02-28 2024-10-25 一般社団法人 Unical ヒトによる経口摂取のためのカルシウム組成物
AU2023378960A1 (en) * 2022-11-08 2025-06-12 Amorphical Ltd. Methods for preparing amorphous calcium carbonate by fixation of carbon dioxide
WO2026044304A1 (en) * 2024-08-20 2026-02-26 Clarke Black Kim Jean A health supplement composition, and a method of manufacturing a health supplement composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008041236A2 (en) * 2006-10-05 2008-04-10 Ben-Gurion University Of The Negev Research And Development Authority Composition comprising crustacean gastrolith components, calcium carbonate and its use
WO2009053967A1 (en) * 2007-10-22 2009-04-30 Amorphical Ltd. Stable amorphous calcium carbonate comprising phosphorylated amino acids, synthetic phosphorylated peptides, and gastrolith proteins

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0304987B1 (en) * 1987-08-28 1992-11-11 Norwich Eaton Pharmaceuticals, Inc. Novel calcium supplements
CA1336328C (en) 1988-04-11 1995-07-18 Walter G. Leonard Method of increasing bone density in humans
WO1997024069A1 (en) 1995-12-26 1997-07-10 Holomed Aps A method and system for generating an x-ray image
JPH10236957A (ja) 1997-02-24 1998-09-08 Bankaku Souhonpo:Kk 骨粗鬆症の改善剤
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
JP2003292453A (ja) 2002-04-02 2003-10-15 Asahi Kasei Corp 骨疾患治療用医薬複合剤
US7267832B2 (en) * 2004-02-18 2007-09-11 Kraft Foods Holdings, Inc. Amorphous water-soluble calcium citrate salts and method of making and using same
ES2447747T3 (es) * 2004-05-26 2014-03-12 Ben Gurion University Of The Negev Research And Development Authority Composiciones administrables por vía oral que comprenden carbonato cálcico amorfo estable
US20070041506A1 (en) 2005-08-22 2007-02-22 Michelle Bottino Digital sensor holder
GB0522045D0 (en) 2005-10-28 2005-12-07 Novartis Ag Pharmaceutical compositions
WO2009087553A1 (en) 2008-01-02 2009-07-16 Aurobindo Pharma Limited Kits for administering bisphosphonates
CN101314031A (zh) 2008-07-14 2008-12-03 王冰 一种改善骨营养的制剂
WO2010045558A1 (en) * 2008-10-17 2010-04-22 Fresenius Medical Care Holdings, Inc. Method of determining a phosphorus binder dosage for a dialysis patient
CN102085356B (zh) 2010-12-28 2013-02-27 北京同仁堂健康药业股份有限公司 一种用于增加骨密度的组合物及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008041236A2 (en) * 2006-10-05 2008-04-10 Ben-Gurion University Of The Negev Research And Development Authority Composition comprising crustacean gastrolith components, calcium carbonate and its use
WO2009053967A1 (en) * 2007-10-22 2009-04-30 Amorphical Ltd. Stable amorphous calcium carbonate comprising phosphorylated amino acids, synthetic phosphorylated peptides, and gastrolith proteins

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107921060A (zh) * 2015-06-04 2018-04-17 艾玛菲克有限公司 用于吸入施用、舌下施用或含服施用的无定形碳酸钙的组合物
CN108778296A (zh) * 2016-01-18 2018-11-09 艾玛菲克有限公司 治疗神经、肌肉和不育疾病或状况的稳定的无定形碳酸钙
CN108778296B (zh) * 2016-01-18 2024-07-09 艾玛菲克有限公司 治疗神经、肌肉和不育疾病或状况的稳定的无定形碳酸钙
CN110121351A (zh) * 2016-10-25 2019-08-13 艾玛菲克有限公司 用于治疗白血病的无定形碳酸钙
CN110123836A (zh) * 2019-05-20 2019-08-16 昆明朗盛生物科技有限公司 钙锌维生素d泛酸片的应用

Also Published As

Publication number Publication date
AU2017279824A1 (en) 2018-01-25
JP2018138591A (ja) 2018-09-06
IL233107B (en) 2020-06-30
AU2012354056A1 (en) 2014-07-10
EP2790710A1 (en) 2014-10-22
IL274755A (en) 2020-07-30
US20150056306A1 (en) 2015-02-26
AU2020200704A1 (en) 2020-02-20
US10064890B2 (en) 2018-09-04
JP2019214631A (ja) 2019-12-19
JP2015500333A (ja) 2015-01-05
CA2859122C (en) 2019-11-05
DK2790710T3 (da) 2020-11-30
CA2859122A1 (en) 2013-06-20
US10688124B2 (en) 2020-06-23
AU2012354056B2 (en) 2017-10-05
EP2790710B1 (en) 2020-08-26
AU2012354056A8 (en) 2017-10-12
IL274755B (en) 2021-04-29
ES2831699T3 (es) 2021-06-09
WO2013088440A1 (en) 2013-06-20
US20190022133A1 (en) 2019-01-24
CA3056570C (en) 2022-04-19
EP2790710A4 (en) 2015-11-11
WO2013088440A8 (en) 2013-08-01
CA3056570A1 (en) 2013-06-20
CN109568338A (zh) 2019-04-05
IL233107A0 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
US10688124B2 (en) Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders
Reid et al. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis
Krause et al. Calcium gluconate supplementation is effective to balance calcium homeostasis in patients with gastrectomy
Itoh et al. The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis
CN103893746A (zh) 含有pth的骨质疏松症治疗/预防剂
Oh et al. Three pediatric patients with primary hyperparathyroidism caused by parathyroid adenoma
Reginster et al. Strontium ranelate: a new paradigm in the treatment of osteoporosis
TW200412979A (en) Method for preventing or reducing secondary fractures after hip fracture
Atamaz et al. The prevention of bone fractures after liver transplantation: experience with alendronate treatment
Nordborg et al. The ineffectiveness of cyclical oral clodronate on bone mineral density in glucocorticoid‐treated patients with giant‐cell arteritis
Ohbayashi et al. Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (6), assessment of mandibular metabolism due to long-term administration of an anti-resorptive agent by bone scintigraphy (secondary publication)
Goyal et al. Brown tumor as an index presentation of severe vitamin D deficiency in a teenage girl
Fujita et al. Clinical effect of bisphosphonate and vitamin D on osteoporosis: reappraisal of a multicenter double-blind clinical trial comparing etidronate and alfacalcidol
Iwamoto et al. RETRACTED ARTICLE: Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients
Hamzah et al. Association between Vitamin D and Calcium Level and BMD Alteration in Post-Menopausal Osteoporosis Patients Treated with Bisphosphonate Therapy for at Least 1 Year in Saiful Anwar Hospital Malang
CN1325058C (zh) 亚硒酸钠在制备治疗风湿寒性关节痛药物中的应用
CN100340243C (zh) 亚硒酸钠在制备骨性关节炎药物中的应用
Jensen et al. Nephrocalcinosis: a potential complication of bisphosphonate therapy in children.
Jain et al. Absorption, Scintigraphy, Efficacy and Tolerability of Short-Term Calcium Carbonate Supplementation in Healthy Subjects
Manette et al. Comprehensive therapy in osteoporosis using a single drug: from ADFR to strontium ranelate
Caseja et al. Rebound-Associated Vertebral Fractures Two Months After a Missed Dose of Denosumab
Goss The role of gastric pH and bicarbonate secretion in intestinal absorption of calcium from supplements
Pandit Determination of Serum Vitamin D Levels in Completely Edentulous Patients
Mazed in 10 easy steps
Months Bone and Mineral Metabolism

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20141022

RJ01 Rejection of invention patent application after publication